Epicardial-derived paracrine factors for repairing cardiac tissue
AssigneesRegencor, Inc., Sanford Burnham Prebys Medical Discovery Institute
InventorsPilar Ruiz-Lozano, Mark Mercola, Ke Wei
Life of this patent
Estimating the term…
Abstract
Provided herein, inter alia, are compositions and kits comprising epicardial-derived paracrine factors (such as, hypoglycosylated follistatin-like 1 (FSTL1)) for treating and repairing damage to cardiac tissue caused by cardiovascular disease, myocardial infarction (MI), other ischemic events, or cardiac-growth deficiency, as well as methods for using the same.
Claims21
1-72. (canceled)
A pharmaceutical composition, comprising a hypoglycosylated follistatin-like 1 (FSTL1) polypeptide and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is formulated for subcutaneous administration.
A method of producing a hypoglycosylated follistatin-like 1 (FSTL1) polypeptide, comprising culturing a host cell, wherein the host cell comprises a nucleic acid encoding an FSTL1 polypeptide, wherein the FSTL1 polypeptide is a hypoglycosylated FSTL1 polypeptide, wherein the hypoglycosylated FSTL1 polypeptide (a) lacks N-linked glycosylation at one or more glycosylation-competent residues;
- and/or (b) comprises substitution of the one or more glycosylation-competent residues with one or more glycosylation incompetent residues.
A hypoglycosylated follistatin-like 1 (FSTL1) polypeptide, produced by a process comprising the steps of
- (a) providing a nucleic acid encoding an FSTL1 polypeptide, wherein the FSTL1 polypeptide comprises substitution of one or more glycosylation-competent residues with one or more glycosylation incompetent residues;
- (b) contacting the nucleic acid with a host cell, optionally treating the host cell with an inhibitor of glycosylation;
- and
- (c) optionally isolating the hypoglycosylated FSTL1 polypeptide.
Dependencies are inferred from the claim text.